Target Audience of Mycoplasma Testing Market: Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies.
Mycoplasma Testing Market Report provides key statistics on the market status of the Mycoplasma Testing Key-players/Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Industry
The global mycoplasma testing market is expected to register a CAGR of 10.4% during the forecast period of 2018–2023. North America is anticipated to dominate the market during the forecast period owing to the large number of life science research activities conducted in this region.
High Spending into R&D Activities by Bio-pharmaceutical Companies
The R&D spending by pharmaceutical companies has been steadily increasing over the past few years, both in the developed and the emerging countries. This was mainly attributed to the increased number of patent expirations, which resulted in a patent cliff in 2012 and is expected to continue for another decade. As a result of the patent expiration, most blockbuster molecules will no longer be able to generate revenue and pharmaceutical companies have no other option but to develop new revolutionary molecules for survival. Therefore, the companies are increasing their spending on R&D to accelerate the process of drug discovery and development. Mycoplasma detection and removal is critical for biologics produced for clinical studies and licensed products for human use. Thus, increase in drug discovery and development process from pharmaceutical companies is likely to augment the demand for mycoplasma testing, which will drive the global mycoplasma testing market. Additionally, increased governmental initiatives and funding in research activities, increasing demand for fast, accurate and affordable testing, and increasing cell culture contamination are further driving the market for mycoplasma testing.
Stringent Government Regulations
Stringent government regulations are likely to hinder the mycoplasma testing market growth. The regulations implemented include the assessment of nutritive properties of the solid growth media (agar) used, the assessment of inhibitory substances in the test material, the incubation temperature ranges to be used, and the number and types of positive controls to be used. These stringent government regulations act as the major restraining factors for the market. Additionally, a high degree of consolidation for new entrants may impede the market.
North America to Dominate the Market
North America dominates the mycoplasma testing market. The factors attributing to the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment into R&D activities in the region. Asia-Pacific is anticipated to grow tremendously during the forecast period owing to factors, such as rapid research activities conducted by the pharmaceutical and biotechnology industries and the huge amount of spending in R&D activities, thereby boosting the demand for mycoplasma testingproducts.
Get PDF Sample of Mycoplasma Testing Market Report @ https://www.360marketupdates.com/enquiry/request-sample/12886559
Major companies covered in this Report:
- Agilent Technologies
- Charles River Laboratories International
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- Lonza Group
- Merck Kgaa
- Promocell Gmbh
- Sartorius Ag
- Thermo Fisher Scientific
Reasons to Purchase the Report
Purchase Mycoplasma Testing Market Report at $ 4250(SUL) @ https://www.360marketupdates.com/purchase/12886559
This Mycoplasma Testing market report offers an overview of the market trends, drivers, and barriers with respect to the market. A detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Mycoplasma Testing market.